← Leaderboards
Dale L Boger
Scripps Research Institute, The
$41,942,040
Attributed
$46,288,227
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$46,288,227 · 12
By mechanism
R01$36,059,709 · 7
U24$3,807,835 · 1
R37$3,352,500 · 1
P01$3,068,183 · 3
Top collaborators
- Bruce A Beutler6 shared
- Benjamin F Cravatt5 shared
- Brunhilde Felding-Habermann5 shared
Most similar at Scripps Research Institute, The
Same institution · by research overlap
- Colin Keith Skepper$34,882
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignAnalogEvaluationBiologicalStructurePropertyReactionGrantIn VivoProteinsAntineoplastic AntibioticsSitePharmaceutical PreparationsEnzymesInnovationCancer TherapyDiels Alder ReactionBaseLibrariesAmidesDrug Design /Synthesis /ProductionSeriesNovel StrategiesResistance
Grant awards (119)
Modulating Signaling Endocannabinoids and Fatty Acid Amides$414,000
R37 · FY2025 · DA · contact PI
Biologically Active Cyclic Peptides$436,584
R01 · FY2024 · CA · contact PI
Antitumor Antibiotics$417,702
R01 · FY2024 · CA · contact PI
Modulating Signaling Endocannabinoids and Fatty Acid Amides$407,250
R37 · FY2024 · DA · contact PI
Biologically Active Cyclic Peptides$459,563
R01 · FY2023 · CA · contact PI
Antitumor Antibiotics$430,894
R01 · FY2023 · CA · contact PI
Modulating Signaling Endocannabinoids and Fatty Acid Amides$399,375
R37 · FY2023 · DA · contact PI
Biologically Active Cyclic Peptides$450,371
R01 · FY2022 · CA · contact PI
Antitumor Antibiotics$422,559
R01 · FY2022 · CA · contact PI
Modulating Signaling Endocannabinoids and Fatty Acid Amides$399,375
R37 · FY2022 · DA · contact PI
A Unique Class of Reductively Activated Oncology Drugs$718,986
R01 · FY2021 · CA · contact PI
Biologically Active Cyclic Peptides$459,563
R01 · FY2021 · CA · contact PI
Modulating Signaling Endocannabinoids and Fatty Acid Amides$433,125
R37 · FY2021 · DA · contact PI
Antitumor Antibiotics$431,185
R01 · FY2021 · CA · contact PI
A Unique Class of Reductively Activated Oncology Drugs$718,986
R01 · FY2020 · CA · contact PI
Biologically Active Cyclic Peptides$459,563
R01 · FY2020 · CA · contact PI
Modulating Signaling Endocannabinoids and Fatty Acid Amides$433,125
R37 · FY2020 · DA · contact PI
Antitumor Antibiotics$431,185
R01 · FY2020 · CA · contact PI
A Unique Class of Reductively Activated Oncology Drugs$697,415
R01 · FY2019 · CA · contact PI
Modulating Signaling Endocannabinoids and Fatty Acid Amides$433,125
R37 · FY2019 · DA · contact PI
Biologically Active Cyclic Peptides$399,124
R01 · FY2019 · CA · contact PI
A Unique Class of Reductively Activated Oncology Drugs$718,986
R01 · FY2018 · CA · contact PI
Antitumor Antibiotics$462,801
R01 · FY2018 · CA · contact PI
Modulating Signaling Endocannabinoids and Fatty Acid Amides$433,125
R37 · FY2018 · DA · contact PI
Biologically Active Cyclic Peptides$411,469
R01 · FY2018 · CA · contact PI
A Unique Class of Reductively Activated Oncology Drugs$718,986
R01 · FY2017 · CA · contact PI
Antitumor Antibiotics$462,801
R01 · FY2017 · CA · contact PI
Modulating Signaling Endocannabinoids and Fatty Acid Amides$433,125
R01 · FY2017 · DA · contact PI
Biologically Active Cyclic Peptides$411,469
R01 · FY2017 · CA · contact PI
Antitumor Antibiotics$462,801
R01 · FY2016 · CA · contact PI
Biologically Active Cyclic Peptides$405,056
R01 · FY2016 · CA · contact PI
Antitumor Antibiotics$462,801
R01 · FY2015 · CA · contact PI
Biologically Active Cyclic Peptides$405,056
R01 · FY2015 · CA · contact PI
Vindoline and Vinblastine$327,298
R01 · FY2015 · CA · contact PI
Antitumor Antibiotics$462,801
R01 · FY2014 · CA · contact PI
Inhibitors of Fatty Acid Amide Hydrolase (FAAH)$414,457
R01 · FY2014 · DA · contact PI
Biologically Active Cyclic Peptides$371,147
R01 · FY2014 · CA · contact PI
Vindoline and Vinblastine$317,479
R01 · FY2014 · CA · contact PI
Discovery and Analysis of Synthetic TLR Agonists and Antagonists$612,337
U24 · FY2013 · AI · contact PI
Antitumor Antibiotics$440,353
R01 · FY2013 · CA · contact PI
Inhibitors of Fatty Acid Amide Hydrolase (FAAH)$397,879
R01 · FY2013 · DA · contact PI
Biologically Active Cyclic Peptides$359,669
R01 · FY2013 · CA · contact PI
Vindoline and Vinblastine$307,660
R01 · FY2013 · CA · contact PI
Endocannabioid Metabolic Enzymes; Structures, Function, In Vivo Inhibition$253,719
P01 · FY2013 · DA
Discovery and Analysis of Synthetic TLR Agonists and Antagonists$651,422
U24 · FY2012 · AI · contact PI
Antitumor Antibiotics$470,318
R01 · FY2012 · CA · contact PI
Inhibitors of Fatty Acid Amide Hydrolase (FAAH)$414,457
R01 · FY2012 · DA · contact PI
Biologically Active Cyclic Peptides$375,123
R01 · FY2012 · CA · contact PI
Vindoline and Vinblastine$327,298
R01 · FY2012 · CA · contact PI
Endocannabioid Metabolic Enzymes; Structures, Function, In Vivo Inhibition$264,982
P01 · FY2012 · DA
Discovery and Analysis of Synthetic TLR Agonists and Antagonists$651,422
U24 · FY2011 · AI · contact PI
Antitumor Antibiotics$472,229
R01 · FY2011 · CA · contact PI
Inhibitors of Fatty Acid Amide Hydrolase (FAAH)$414,457
R01 · FY2011 · DA · contact PI
The Antitumor Antibiotics CC-1065 and the Duocarmycins$396,544
R01 · FY2011 · CA · contact PI
Biologically Active Cyclic Peptides$382,626
R01 · FY2011 · CA · contact PI
Vindoline and Vinblastine$327,298
R01 · FY2011 · CA · contact PI
Endocannabioid Metabolic Enzymes; Structures, Function, In Vivo Inhibition$265,713
P01 · FY2011 · DA
Discovery and Analysis of Synthetic TLR Agonists and Antagonists$658,004
U24 · FY2010 · AI
Antitumor Antibiotics$487,268
R01 · FY2010 · CA · contact PI
Inhibitors of Fatty Acid Amide Hydrolase (FAAH)$427,275
R01 · FY2010 · DA · contact PI
The Antitumor Antibiotics CC-1065 and the Duocarmycins$408,808
R01 · FY2010 · CA · contact PI
Vindoline and Vinblastine$326,609
R01 · FY2010 · CA · contact PI
Endocannabioid Metabolic Enzymes; Structures, Function, In Vivo Inhibition$265,953
P01 · FY2010 · DA
Discovery and Analysis of Synthetic TLR Agonists and Antagonists$664,650
U24 · FY2009 · AI
Discovery and Analysis of Synthetic TLR Agonists and Antagonists$570,000
U24 · FY2009 · AI
Antitumor Antibiotics$477,714
R01 · FY2009 · CA · contact PI
The Antitumor Antibiotics CC-1065 and the Duocarmycins$408,808
R01 · FY2009 · CA · contact PI
Biologically Active Cyclic Peptides$381,820
R01 · FY2009 · CA · contact PI
Vindoline and Vinblastine$326,609
R01 · FY2009 · CA · contact PI
Endocannabioid Metabolic Enzymes; Structures, Function, In Vivo Inhibition$260,814
P01 · FY2009 · DA
Antitumor Antibiotics$458,616
R01 · FY2008 · CA · contact PI
The Antitumor Antibiotics CC-1065 and the Duocarmycins$408,808
R01 · FY2008 · CA · contact PI
Biologically Active Cyclic Peptides$381,820
R01 · FY2008 · CA · contact PI
Combinatorial Libraries and Cellular Signaling$365,525
P01 · FY2008 · CA · contact PI
Vindoline and Vinblastine$326,609
R01 · FY2008 · CA · contact PI
Instrument Core$135,773
P01 · FY2008 · CA · contact PI
Antitumor Antibiotics$451,316
R01 · FY2007 · CA · contact PI
The Antitumor Antibiotics CC-1065 and the Duocarmycins$402,121
R01 · FY2007 · CA · contact PI
Biologically Active Cyclic Peptides$374,566
R01 · FY2007 · CA · contact PI
Combinatorial Libraries and Cellular Signaling$358,664
P01 · FY2007 · CA · contact PI
Vindoline and Vinblastine$320,404
R01 · FY2007 · CA · contact PI
Instrument Core$133,386
P01 · FY2007 · CA · contact PI
Antitumor Antibiotics$452,810
R01 · FY2006 · CA · contact PI
Biologically Active Cyclic Peptides$385,754
R01 · FY2006 · CA · contact PI
Vindoline and Vinblastine$329,973
R01 · FY2006 · CA · contact PI
Inhibitors of Fatty Acid Amide Hydrolase (FAAH)$226,061
R01 · FY2006 · DA · contact PI
Combinatorial Libraries and Cellular Signaling$186,328
P01 · FY2006 · CA · contact PI
Instrument Core$73,908
P01 · FY2006 · CA · contact PI
Antitumor Antibiotics$476,150
R01 · FY2005 · CA
THE ANTITUMOR ANTIBIOTICS CC-1065 AND THE DUOCARMYCINS$396,986
R01 · FY2005 · CA
Biologically Active Cyclic Peptides$395,038
R01 · FY2005 · CA
Fostriecin and Related Protein Phosphatase Inhibitors$370,863
R01 · FY2005 · CA
Inhibitors of Fatty Acid Amide Hydrolase (FAAH)$231,500
R01 · FY2005 · DA
Combinatorial Libraries and Cellular Signaling$181,167
P01 · FY2005 · CA
Instrument Core$73,745
P01 · FY2005 · CA
Antitumor Antibiotics$438,009
R01 · FY2004 · CA
THE ANTITUMOR ANTIBIOTICS CC-1065 AND THE DUOCARMYCINS$396,986
R01 · FY2004 · CA
BIOLOGICALLY ACTIVE CYCLIC PEPTIDES$375,030
R01 · FY2004 · CA
Fostriecin and Related Protein Phosphatase Inhibitors$370,863
R01 · FY2004 · CA
Inhibitors of Fatty Acid Amide Hydrolase (FAAH)$231,500
R01 · FY2004 · DA
Combinatorial Libraries and Cellular Signaling$175,891
P01 · FY2004 · CA
Instrument Core$72,615
P01 · FY2004 · CA
THE ANTITUMOR ANTIBIOTICS CC-1065 AND THE DUOCARMYCINS$396,986
R01 · FY2003 · CA
ANTITUMOR ANTIBIOTICS$392,514
R01 · FY2003 · CA
BIOLOGICALLY ACTIVE CYCLIC PEPTIDES$375,030
R01 · FY2003 · CA
Fostriecin and Related Protein Phosphatase Inhibitors$370,863
R01 · FY2003 · CA
Inhibitors of Fatty Acid Amide Hydrolase (FAAH)$231,500
R01 · FY2003 · DA
ANTITUMOR ANTIBIOTICS$385,180
R01 · FY2002 · CA
BIOLOGICALLY ACTIVE CYCLIC PEPTIDES$375,030
R01 · FY2002 · CA
Fostriecin and Related Protein Phosphatase Inhibitors$370,863
R01 · FY2002 · CA
Inhibitors of Fatty Acid Amide Hydrolase (FAAH)$231,500
R01 · FY2002 · DA
ANTITUMOR ANTIBIOTICS$360,522
R01 · FY2001 · CA
BIOLOGICALLY ACTIVE CYCLIC PEPTIDES$359,033
R01 · FY2001 · CA
ANTITUMOR ANTIBIOTICS--CC-1065 AND THE DUOCARMYCINS$320,096
R01 · FY2001 · CA
ANTITUMOR ANTIBIOTICS--CC-1065 AND THE DUOCARMYCINS$79,631
R01 · FY2001 · CA
BIOLOGICALLY ACTIVE CYCLIC PEPTIDES$359,033
R01 · FY2000 · CA
ANTITUMOR ANTIBIOTICS$353,891
R01 · FY2000 · CA
ANTITUMOR ANTIBIOTICS--CC-1065 AND THE DUOCARMYCINS$314,095
R01 · FY2000 · CA
ANTITUMOR ANTIBIOTICS--CC-1065 AND THE DUOCARMYCINS$69,124
R01 · FY2000 · CA